Literature DB >> 1827495

Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism.

S Fukui1, R Schwarcz, S I Rapoport, Y Takada, Q R Smith.   

Abstract

To evaluate the potential contribution of circulating kynurenines to brain kynurenine pools, the rates of cerebral uptake and mechanisms of blood-brain barrier transport were determined for several kynurenine metabolites of tryptophan, including L-kynurenine (L-KYN), 3-hydroxykynurenine (3-HKYN), 3-hydroxyanthranilic acid (3-HANA), anthranilic acid (ANA), kynurenic acid (KYNA), and quinolinic acid (QUIN), in pentobarbital-anesthetized rats using an in situ brain perfusion technique. L-KYN was found to be taken up into brain at a significant rate [permeability-surface area product (PA) = 2-3 x 10(-3) ml/s/g] by the large neutral amino acid carrier (L-system) of the blood-brain barrier. Best-fit estimates of the Vmax and Km of saturable L-KYN transfer equalled 4.5 x 10(-4) mumol/s/g and 0.16 mumol/ml, respectively. The same carrier may also mediate the brain uptake of 3-HKYN as D,L-3-HKYN competitively inhibited the brain transfer of the large neutral amino acid L-leucine. For the other metabolites, uptake appeared mediated by passive diffusion. This occurred at a significant rate for ANA (PA, 0.7-1.6 x 10(-3) ml/s/g), and at far lower rates (PA, 2-7 x 10(-5) ml/s/g) for 3-HANA, KYNA, and QUIN. Transfer for KYNA, 3-HANA, and ANA also appeared to be limited by plasma protein binding. The results demonstrate the saturable transfer of L-KYN across the blood-brain barrier and suggest that circulating L-KYN, 3-HKYN, and ANA may each contribute significantly to respective cerebral pools. In contrast, QUIN, KYNA, and 3-HANA cross the blood-brain barrier poorly, and therefore are not expected to contribute significantly to brain pools under normal conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827495     DOI: 10.1111/j.1471-4159.1991.tb03460.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  220 in total

1.  Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Howard M Eisenberg; Yasushi Kajii; Robert Schwarcz; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

2.  Accumulation of toxic products degradation of kynurenine in hemodialyzed patients.

Authors:  D Pawlak; K Pawlak; J Malyszko; M Mysliwiec; W Buczko
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

3.  Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Greg I Elmer; John P Bruno; Robert Schwarcz
Journal:  Eur J Neurosci       Date:  2012-04-20       Impact factor: 3.386

4.  Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Laura Amori; Paolo Guidetti; Paul J Muchowski; Robert Schwarcz
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

5.  Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.

Authors:  Dénes Zádori; Gábor Nyiri; András Szonyi; István Szatmári; Ferenc Fülöp; József Toldi; Tamás F Freund; László Vécsei; Péter Klivényi
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

6.  Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing.

Authors:  Donald M Lamkin; Susan K Lutgendorf; David Lubaroff; Anil K Sood; Terry G Beltz; Alan Kim Johnson
Journal:  Brain Behav Immun       Date:  2010-12-21       Impact factor: 7.217

7.  Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring.

Authors:  Silas A Buck; Annalisa M Baratta; Ana Pocivavsek
Journal:  Neurobiol Learn Mem       Date:  2020-07-30       Impact factor: 2.877

Review 8.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-04-18       Impact factor: 7.853

10.  A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study.

Authors:  Máté Marosi; Dávid Nagy; Tamás Farkas; Zsolt Kis; Eva Rózsa; Hermina Robotka; Ferenc Fülöp; László Vécsei; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2009-12-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.